Vivace Therapeutics, Inc is recruiting patients for a PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma.
The trial, designated NCT04665206, aims to enroll up to 336 participants at 12 sites, including locations in California, Illinois, Massachusetts.
About the Study
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Treatment Approach
This trial uses a combination of checkpoint inhibitors that was FDA-approved for mesothelioma in 2020.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: Vivace Therapeutics, Inc
- Enrollment target: 336
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- UCSF Helen Diller Family Comprehensive Cancer Center, California
- University of Chicago Medical Center, Illinois
- Massachusetts General Hospital, Massachusetts
- Dana-Farber Cancer Institute, Massachusetts
- M Health Fairview University of Minnesota Medical Center, Minnesota
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening